Actively Recruiting
A Trial of Shengmai Liquid for Long COVID Fatigue.
Led by Beijing University of Chinese Medicine · Updated on 2026-02-09
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
B
Beijing University of Chinese Medicine
Lead Sponsor
I
Institute of Chemistry - Vietnam Academy of Science and Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Shengmai liquid works to treat Long Covid fatigue. It will also learn about the safety of Shengmai liquid. The main questions it aims to answer are: * Dose the Shengmai liquid will reduce the level of fatigue in the participants and reduce the fatigue scale score of the participants? * Dose the Shengmai liquid will reduce the level of anxiety and depression in the participants and improve the sleep quality and quality of life of the participants Researchers will compare Shengmai oral liquid to a placebo (a look-alike substance that contains no drug) to see if Shengmai liquid works to treat Long Covid fatigue. Participants will: * Take Shengmai liquid or a placebo every day for 8 weeks. * Visit the clinic once every 4 weeks for check up and test. There are a total of two telephone follow-ups, one follow-up 15 days after the treatment starts and another follow-up 30 days after the treatment ends. * Participants' medication responses and scale scores will be recorded.
CONDITIONS
Official Title
A Trial of Shengmai Liquid for Long COVID Fatigue.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 75 years
- Meet the diagnostic criteria for Long COVID fatigue
- Meet the traditional Chinese medicine syndrome diagnostic criteria
- Provide informed consent and sign the consent form
You will not qualify if you...
- Need or expect to need advanced respiratory support such as high-flow oxygen, positive pressure ventilation, invasive mechanical ventilation, or ECMO
- Have active liver disease or liver function tests showing ALT >3x ULN, AST >3x ULN, or bilirubin >2x ULN
- Undergoing dialysis or have moderate to severe renal impairment (eGFR ≤45 mL/min/1.73 m² within 6 months before screening)
- Have moderate to severe congestive heart failure, recent stroke, myocardial infarction, coronary artery stent implantation, uncontrolled hypertension, or significant ECG abnormalities
- Had influenza A, influenza B, or other infectious diseases within 3 months before screening
- Have severe neurological diseases, mental illness, or family history of mental illness
- Are pregnant or breastfeeding, or have a positive pregnancy test before medication
- Have a history of malignant tumors within 5 years or active tumors expected to require treatment during the study
- Have chronic fatigue syndrome or autoimmune diseases such as rheumatoid arthritis or lupus
- Known allergy to any component of the study drug
- Have diseases that the investigator judges unsuitable for study participation
- Taken traditional Chinese medicine containing Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, or Astragalus membranaceus within 2 weeks before screening
- Participating in other drug or medical device-related studies at the same time
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Di Tan Hospital, , Capital Medical University
Beijing, China, China, 102488
Actively Recruiting
Research Team
H
Huijuan Cao, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here